Last updated: February 24, 2026
What Is the Specific Use and Market Context for NDC 00904-7024?
NDC 00904-7024 is the publicly listed identifier for a medication marketed by Akorn, Inc. It is a sterile ophthalmic solution, primarily used for treating allergic conjunctivitis or other eye-related inflammatory conditions. It contains ketotifen fumarate, an antihistamine with mast cell stabilizer properties.
The product addresses a specialized segment in ophthalmology, competing with branded and generic antihistamine eye drops. It was approved by the FDA in 2015 and is marketed as a generic alternative.
How Does the Market Size and Competitive Landscape Look?
Market Size
The US ophthalmic antihistamine market was valued at approximately $350 million in 2022. The segment is expected to grow at a compound annual growth rate (CAGR) of 3.5% to 4.0% through 2027, driven by increased prevalence of allergic rhinitis and conjunctivitis, and rising awareness of treatment options.
Competitive Landscape
The market features several key players:
- Alaway (ketotifen fumarate ophthalmic solution): Market leader with roughly 60% share.
- Zaditor (ketotifen fumarate): Competes directly.
- Generic formulations: Include versions from brands like Akorn, Sandoz, and Sun Pharma, accounting for approximately 30% of sales.
Regulatory and Patent Status
Akorn’s product does not hold current patent protections, allowing entry of generics. The FDA approval process for generics relies on bioequivalence, with no complex formulation hurdles reported.
What Are the Pricing Trends and Projections?
Current Pricing (2023)
- Brand versions: Sale prices generally range from $40 to $60 per 10 mL bottle.
- Generic (Akorn): Wholesale acquisition cost (WAC) typically stands around $20 to $30 per bottle.
Historical Pricing Trends
- Between 2020 and 2022, the average retail price for branded versions decreased by 10-15%.
- Generic introductions in 2016-2018 helped reduce the average price levels.
Price Projection (2024–2028)
- Short-term (next 1-2 years): Stable, with prices remaining within the current range due to existing competition and limited market expansion.
- Medium-term (3-5 years): Potential price decline of 10% to 15% for generics, driven by increased competition and potential biosimilar/copycat entries.
- Long-term: Prices could stabilize or slightly decline further as manufacturing efficiencies improve and patent expirations free the market from exclusivity constraints.
Factors Impacting Future Prices
- Patent expirations: No recent patents for NDC 00904-7024; market saturation possible.
- Market penetration: Growing awareness may drive volume, not necessarily higher prices.
- Regulatory policies: Policies encouraging generic use can press prices downward.
- Manufacturing costs: Expected to decrease with technological advances, pressuring retail prices.
How Do External Risks and Market Dynamics Influence Price and Market Volume?
- Regulatory changes: Stricter approval pathways or biosimilar pathways could alter market entry.
- Reimbursement policies: Payor preferences toward generics could expand access, increasing volume.
- Patent and intellectual property disputes: Absence of active patents indicates low litigation risk for generics.
- Background competition: Dominance by Alaway and Zaditor limits upside for new entrants without differentiation.
What Are the Strategic Implications for Stakeholders?
- Pharmaceutical companies: Entry of low-cost generics has normalized pricing; innovation on formulations or delivery systems may offer differentiation.
- Investors: The stable market with modest growth and declining prices suggests limited upside unless new formulations or indications emerge.
- Manufacturers: Cost reductions and efficient supply chain management can preserve margins despite pricing pressures.
Key Takeaways
- NDC 00904-7024 is a generic ketotifen fumarate ophthalmic solution launched in 2015.
- The medication operates in a mature, competitive market with an estimated size of $350 million in the US.
- Current retail prices for generics hover around $20-30 per bottle, with limited room for significant price increases.
- Future price declines of 10-15% are projected over the next five years due to increased generic competition.
- Market growth is driven by rising prevalence of allergic eye conditions and a shift toward generic utilization, rather than premium pricing.
FAQs
1. When will NDC 00904-7024 lose patent exclusivity?
Since it is a generic product approved in 2015, no patents are currently in force, allowing multiple competitors to enter the market freely.
2. Are there any upcoming regulatory hurdles that could impact pricing?
No major regulatory hurdles are expected for this core formulation; however, future claims related to new indications or delivery methods could alter the competitive landscape.
3. How does emerging biosimilar or novel delivery system competition affect this market?
The ophthalmic antihistamine market is unlikely to see biosimilar or biologic innovation, but new delivery methods (e.g., sustained-release drops) could disrupt pricing and market share.
4. What is the long-term sales outlook for this medication?
Market size growth remains modest, with total sales likely stabilizing or slightly declining as consumer preference shifts to newer treatment options or formulations.
5. Could price reductions impact profitability for manufacturers?
Yes, especially if competition intensifies or reimbursement policies favor low-cost generics, pressuring margins.
References
- MarketResearch.com. (2022). US ophthalmic antihistamine market analysis.
- FDA. (2015). Approval Letter for Ketotifen Fumarate ophthalmic solution.
- IQVIA. (2022). US pharmaceutical market data.
- Healthcare Innovation Group. (2023). Trends in ophthalmic drug pricing.
- Statista. (2023). Consumer prices for ophthalmic solutions.
